Improving genomic surveillance to better understand new variants as they arise in different parts of the world could prevent threats to vulnerable health systems and populations.
Calculating your risk of death or hospitalization if you are infected with the coronavirus requires good data – notably, the total number of infections in the US. Unfortunately, that data is fuzzy.
Countries must be encouraged to distribute essential healthcare provision - like diagnosis - to where people most need them and where they can be accessed more easily.
A new over-the-counter COVID-19 test has been authorized by the FDA. Though it can be used to test people with and without symptoms, moderate cost and limited production mean it isn’t a game-changer.
With a vaccine now approved in the UK, other countries won’t be far behind. But a vaccine won’t singlehandedly ensure the virus doesn’t cross international borders when travel picks up.
In September, production of rapid tests really ramped up in the US. But due to low accuracy and massive numbers needed, these tests alone are unlikely to have much of an effect on the pandemic.
COVID-19 cases are skyrocketing across the US. Testing has ramped up over the past few months, but increasing hospitalizations, deaths and test-positivity rates show that the virus is out of control.
It is important to understand that not everyone should be tested and that the timing and correct use of the different types tests is important in order to gain the best results.
Over the approaching holidays, people around the world will want to travel to see friends and family. Getting tested for the coronavirus can make this safer, but testing alone is not a perfect answer.
States have been experimenting with more targeted approaches to slow the coronavirus’s spread. Two strategies stand out.
The new BinaxNOW antigen test is quick, easy, accurate and cheap. It could solve the US testing problem, but the emergency use authorization only allows people with COVID-19 symptoms to get tested.
Here’s what you need to know about the newer COVID-19 test that’s gentler on your nose.
Testing large numbers of people regularly would reduce the spread of the coronavirus in the US. Laboratory testing is slow and expensive, but rapid screening tests could be the answer.
Test positivity rates measure the success of a testing program. Even though the US performs a huge number of tests, high test positivity rates across the country show that that it still isn’t enough.
A team of researchers from Indiana University performed random testing for SARS-CoV-2 across the state. The results offer some of the most accurate data to date about important aspects of the virus.
For the vast majority of people, no — you don’t need a referral to get tested at dedicated public COVID-19 testing clinic. It’s different if you plan to get tested at a private pathology clinic.
If you’ve got a test but haven’t heard back, it’s possible the delay is caused by test samples needing to be taken to interstate labs and the huge scale of testing underway.
Keeping health-care workers COVID-free is critical to delivering care to those who need it during a pandemic. What can we do to ensure they are better protected?
The prospects of elimination remain elusive but even with the current Victoria outbreak, Australia is maintaining a high number of tests per thousand people.
Pooled testing is most efficient when applied in settings of low virus prevalence.